KOD
HEALTHCAREKodiak Sciences Inc
$45.89+3.23 (+7.57%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KOD Today?
No stock-specific AI insight has been generated for KOD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.81$47.84
$45.89
Fundamentals
Market Cap$2.9B
P/E Ratio—
EPS$-4.32
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding62.2M
KOD News
21 articles- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific ConferencesYahoo Finance·May 1, 2026
- Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?Yahoo Finance·Apr 30, 2026
- Kodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda?Yahoo Finance·Apr 23, 2026
- Russell 2000 Rips To Record High — Here Are The Top Small Cap GainersBenzinga·Apr 17, 2026
- Eagle Eye Solutions Group Leads The Charge In UK Penny StocksYahoo Finance·Apr 13, 2026
- Kodiak Sciences (KOD) Reports Q4 EPS of ($1.05)Yahoo Finance·Apr 12, 2026
- Kodiak Sciences GLOW2 Win Puts Zenkuda And Funding Needs In FocusYahoo Finance·Apr 7, 2026
- Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Momentum And Conflicting SignalsYahoo Finance·Apr 7, 2026
- Sector Update: Health Care Stocks Higher Late AfternoonYahoo Finance·Apr 1, 2026
- Kodiak Q4 Loss Wider Than Expected, Pipeline Development in FocusYahoo Finance·Apr 1, 2026
- Top Midday Stories: Nike Falls After Lower Fiscal Q3 Earnings; FDA Approves Eli Lilly's Obesity PillYahoo Finance·Apr 1, 2026
- Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 31, 2026
- Kodiak Sciences (KOD) Is Up 66.3% After Strong Zenkuda GLOW2 Phase 3 Data - Has The Bull Case Changed?Yahoo Finance·Mar 28, 2026
- KOD Stock Soars on Promising Phase III Data for Eye Disease CandidateYahoo Finance·Mar 27, 2026
- How Kodiak Sciences Stock Rises To $120?Trefis·Mar 27, 2026
- Kodiak Sciences (KOD) Climbs 75% on Stellar Clinical ResultsYahoo Finance·Mar 27, 2026
- Sector Update: Health Care Stocks Advance Thursday AfternoonYahoo Finance·Mar 26, 2026
- Update: Kodiak Shares Rise After Positive Results in Diabetic Retinopathy TrialYahoo Finance·Mar 26, 2026
- Top Midday Stories: Iran Reportedly Sends Formal Response to US Ceasefire Proposal; Corebridge, Equitable to Merge in $22 Billion All-Stock DealYahoo Finance·Mar 26, 2026
- Wall Street Digests Fading Middle East Peace Prospects as US Equity Futures Decline Pre-BellYahoo Finance·Mar 26, 2026
All 21 articles loaded
Price Data
Open$0.00
Previous Close$42.66
Day High$0.00
Day Low$0.00
52 Week High$47.84
52 Week Low$2.81
52-Week Range
$2.81$47.84
$45.89
Fundamentals
Market Cap$2.9B
P/E Ratio—
EPS$-4.32
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding62.2M
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States and international markets. The company is headquartered in Palo Alto, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—